AI assistant
RHYTHM PHARMACEUTICALS, INC. — Director's Dealing 2024
Sep 11, 2024
30849_dirs_2024-09-11_7805c21a-7694-40cd-9892-777b3fc0349b.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: RHYTHM PHARMACEUTICALS, INC. (RYTM)
CIK: 0001649904
Period of Report: 2024-09-09
Reporting Person: TETRAULT LYNN A. (Director)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2024-09-09 | Common Stock | M | 3199 | $18.99 | Acquired | 6199 | Direct |
| 2024-09-09 | Common Stock | S | 3199 | $50.0369 | Disposed | 3000 | Direct |
| 2024-09-10 | Common Stock | M | 10000 | $4.15 | Acquired | 13000 | Direct |
| 2024-09-10 | Common Stock | M | 7501 | $18.99 | Acquired | 20501 | Direct |
| 2024-09-10 | Common Stock | S | 8490 | $49.048 | Disposed | 12011 | Direct |
| 2024-09-10 | Common Stock | S | 8661 | $50.2016 | Disposed | 3350 | Direct |
| 2024-09-10 | Common Stock | S | 350 | $50.5986 | Disposed | 3000 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2024-09-09 | Stock Option (right to buy) | $18.99 | M | 3199 | Disposed | 2031-06-08 | Common Stock (3199) | Direct |
| 2024-09-10 | Stock Option (right to buy) | $4.15 | M | 10000 | Disposed | 2032-06-07 | Common Stock (10000) | Direct |
| 2024-09-10 | Stock Option (right to buy) | $18.99 | M | 7501 | Disposed | 2031-06-08 | Common Stock (7501) | Direct |
Footnotes
F1: The sales reported in the Form 4 were effected pursuant to a Rule 10b5-1 instruction adopted on May 13, 2024.
F2: The price reported is a weighted average price. The securities were sold in multiple transactions at per share prices ranging from $50.00 to $50.25. The Reporting Person undertakes to provide upon request the SEC staff, the Issuer, or any shareholder of the Issuer, full information regarding the number of securities sold at each separate price within the range set forth in this footnote.
F3: The price reported is a weighted average price. The securities were sold in multiple transactions at per share prices ranging from $48.53 to $49.52. The Reporting Person undertakes to provide upon request the SEC staff, the Issuer, or any shareholder of the Issuer, full information regarding the number of securities sold at each separate price within the range set forth in this footnote.
F4: The price reported is a weighted average price. The securities were sold in multiple transactions at per share prices ranging from $49.54 to $50.50. The Reporting Person undertakes to provide upon request the SEC staff, the Issuer, or any shareholder of the Issuer, full information regarding the number of securities sold at each separate price within the range set forth in this footnote.
F5: The price reported is a weighted average price. The securities were sold in multiple transactions at per share prices ranging from $50.55 to $50.71. The Reporting Person undertakes to provide upon request the SEC staff, the Issuer, or any shareholder of the Issuer, full information regarding the number of securities sold at each separate price within the range set forth in this footnote.
F6: The option is fully vested and exercisable.